Inozyme Pharma Inc (INZY) Return on Assets ROA from the first quarter of 2025 to first quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Inozyme Pharma Inc   (NASDAQ: INZY)


Inozyme Pharma Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Inozyme Pharma Inc 's ROA in the first quarter of 2025?
Inozyme Pharma Inc recorded a cumulative net loss of $-107 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -82.5%.

However, within the Healthcare sector 765 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 4428, from total ROA ranking in the fourth quarter of 2024 at 5003.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Total Assets Change -46.13 % -38.67 % -30.31 % 3.17 % 24.57 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -107 -102 -96 -89 -77
Return On Assets (TTM) -82.5 % -68.14 % -57.05 % -47.94 % -42.02 %
INZY's Total Ranking # 4428 # 5003 # 4332 # 4250 # 4227
Total Assets (TTM) in million 95 123 143 156 177
Seq. Total Assets Change -22.75 % -14.08 % -7.93 % -11.85 % -12.05 %
Seq. Net Income Change - - - - -

INZY's 5 Years Annual ROA >> Back to INZY Management Effectiveness >> Compare INZY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 362
Sector # 766
Overall # 4370

Return On Assets Statistics
High Average Low
-31.9 %
-48.14 %
-82.5 %
(Sep 30 2021)   (Mar 31 2025)



  News about Inozyme Pharma Inc Return on Assets ROA

Navigating Rare Discoveries and Financial Recoveries: The Journey of Inozyme Pharma



Inozyme Pharma, a clinical-stage rare disease biopharmaceutical company, recently announced the granting of stock options to three new employees as part of its ongoing efforts to develop novel therapeutics for pathologic mineralization and intimal proliferation. This move comes amid the company s financial struggles, as revealed by its cumulative net loss of $-68 million during the 12 months ending in the third quarter of 2023. With a negative return on assets (ROA) of -42.76%, Inozyme Pharma faces significant challenges within the healthcare sector.
The company s financial performance is cause for concern, particularly when compared to other entities within the healthcare sector. During the same period, 582 other companies posted higher returns on assets, indicating Inozyme Pharma s need for a strategic turnaround. However, there is a glimmer of hope, as the overall ranking for return on assets has improved. Moving up from the total ROA ranking of 4256 in the second quarter of 2023, Inozyme Pharma now stands at 3988 in the rankings for the third quarter of 2023.



Financial Statements
Inozyme Pharma Inc 's Assets $ 95 million INZY's Balance sheet
Inozyme Pharma Inc 's Income $ -28 million Quarterly INZY's Income Statement
INZY's Income by Division See INZY's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change -38.67 % 44.29 % 12.67 % -26.9 % -
Total Assets in million 123 201 139 124 169
Y / Y Net Income Change - - - - -
Net Income in million -102 -71 -67 -57 -56
Annual Return On Assets -82.82 % -35.43 % -48.18 % -45.83 % -33.39 %

INZY's 5 Years Annual ROA >> Back to INZY Management Effectiveness >> Compare INZY ROA to its Competitors



More Return On Assets Ratios
INZY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INZY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INZY's Competitors
Subscribers only: Roa for Inozyme Pharma Inc 's Suppliers
Subscribers only: Return On Assets for INZY's Customers

You may also want to know
INZY's Roi INZY's Inventory Turnover Ratio INZY's Growth Rates INZY's Dividend Comparisons
INZY's Profitability Ratios INZY's Asset Turnover Ratio INZY's Dividend Growth
INZY's Roe INZY's Valuation Ratios INZY's Financial Strength Ratios INZY's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector ROA

Date modified: 2026-09-26T07:38:37+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.